Buprenorphine depot - Camurus

Drug Profile

Buprenorphine depot - Camurus

Alternative Names: Buprenorphine FluidCrystal® injection depot; CAM 2038; CAM2038q1w; CAM2038q4w

Latest Information Update: 09 May 2017

Price : $50

At a glance

  • Originator Camurus
  • Developer Braeburn Pharmaceuticals; Camurus
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Opioid abuse; Pain

Most Recent Events

  • 02 May 2017 Adverse events and pharmacodynamic data from a phase III trial in Opioid abuse released by Braeburn and Camrus
  • 02 May 2017 Braeburn Pharmaceuticals in collaboration with Camrus completes a phase III trial in Opioid abuse in Australia, Sweden, Hungary, Denmark, Germany, USA, United Kingdom (NCT02672111)
  • 14 Nov 2016 Positive top-line efficacy and adverse events data from a phase III trial in Opioid abuse released by Camurus Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top